Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CTX-8371

Bispecific antibody · Antagonist of PD-1 (PDCD1) and PD-L1 (CD274) · developed by Compass Therapeutics

Phase 1 Most advanced trial

CMPS Developer

1 Registered trials

What is CTX-8371?

CTX-8371 is a bispecific tetravalent antibody that simultaneously binds PD-1 on T cells and PD-L1 on tumor cells, crosslinking them and blocking PD-L1/PD-1 signaling. This reverses T-cell inactivation and enhances anti-tumor immune responses. It is studied in non-small cell lung cancer, triple-negative breast cancer, Hodgkin lymphoma, head and neck squamous cell carcinoma, and melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody
Targets: PD-1 (PDCD1), PD-L1 (CD274)
Mechanism: Antagonist of PD-1 (PDCD1) and PD-L1 (CD274)
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Oncology
Developer: Compass Therapeutics (CMPS, CMPX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06150664	Phase 1	Non Small Cell Lung Cancer	Recruiting	CMPS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Squamous Cell CarcinomaHodgkin LymphomaMalignant MelanomaNon Small Cell Lung CancerTriple Negative Breast Cancer

Other drugs acting on PDCD1 / CD274

Berahyaluronidase Alfa and Pembrolizumab FDA approved Durvalumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Acasunlimab Phase 3 AN4005 Phase 1 Atigotatug/Nivolumab Phase 1 AXN-2510 Phase 1 Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3

More from Compass Therapeutics

COMP360 psilocybin Phase 2/3 CTX-10726 Phase 1 CTX-471 Phase 1/2 Psilocybin Phase 3 Tovecimig Phase 2/3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CMPS page.

Follow CMPS, the company behind CTX-8371

See CMPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CMPS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z